[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577162":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":39,"centralContacts":44,"locations":49,"responsibleParty":67,"collaborators":34,"id":69,"slug":34,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":34,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":93,"whyStopped":34,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-model-based prediction group","PLACEBO_COMPARATOR","Heart Faliure Patient Group without diagnosed by multimodal imaging, and they will receive a traditional pharmacological treatment for heart failure.Traditional anti heart failure drug therapy included diuretics, angiotensin-converting enzyme inhibitors (ACEIs)\u002Fangiotensin receptor antagonists (ARBs), beta blockers, positive inotropic drugs, aldosterone receptor blockers (MRA), sodium glucose cotransporter 2 inhibitors (SGLT2i), and retinoids.",[13],"Drug: diuretics, ACEIs\u002FARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids",{"label":15,"type":16,"description":17,"interventionNames":18},"Model-guided optimized treatment","EXPERIMENTAL","Patients with heart failure who were diagnosed in Rare Cardiomypathy by multimodal imaging. And They will receive Close follow-up, intensified pharmacological treatment for heart failure, and early rehabilitation guidance. Traditional anti heart failure drug therapy: diuretics, angiotensin-converting enzyme inhibitors (ACEIs)\u002Fangiotensin receptor antagonists (ARBs), beta blockers, positive inotropic drugs, aldosterone receptor blockers (MRA), sodium glucose cotransporter 2 inhibitors (SGLT2i), and retinoids.",[13,19,20],"Behavioral: Close follow-up","Behavioral: early rehabilitation guidance",[22,29,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","diuretics, ACEIs\u002FARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids","Patients in this group will receive pharmacological treatment for heart failure.",[15,9],[28],"pharmacological treatment for heart failure",{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"BEHAVIORAL","Close follow-up","High risk patients receive close follow-up",[15],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"early rehabilitation guidance","Early rehabilitation guidance such as cardiopulmonary exercise tests and cardiac rehabilitation therapy",[15],[40],{"name":41,"affiliation":42,"role":43},"Meng Jiang, MD, PhD","RenJi Hospital, School of Medicine, Shanghai Jiantong University","STUDY_CHAIR",[45],{"name":41,"role":46,"phone":47,"phoneExt":47,"email":48},"CONTACT","13788912766","jiangmeng0919@163.com",[50],{"facility":51,"status":34,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Renji Hospital","Shanghai","Shanghai Municipality","200030","China",{"type":57,"coordinates":58},"Point",[59,60],121.45806,31.22222,{"lat":60,"lon":59},[63],{"name":64,"role":46,"phone":65,"phoneExt":65,"email":66},"Zi Wang, MD,PHD","15000765160","wangziz10@126.com",{"type":68,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100577162",false,"NCT06794710","Early Identification and Treatment of Rare Cardiomyopathy Cohorts","Early Identification and Treatment of Rare Myocardium by Multimodal Imaging (EARLY-MYO-RARE)","EARLY-MYO-RARE","Inclusion Criteria:\n\n* Age 18-75 years old.\n* Patients preliminarily diagnosed with heart failure and scheduled to receive drug therapy after being evaluated by cardiology departments.\n* No history of structural heart disease, and the Framingham score \\<5 (for patients with the Framingham score ≥5, coronary artery disease will be excluded by coronary angiography\u002Fcoronary CT\u002Fexercise platelet).\n* Creatinine clearance ≥50ml\u002Fmin (Cockcroft-Gault formula).\n* LVEF ≥50% assessed by Echocardiography.\n* QT interval \\< 470 ms.\n* Providing written informed consent.\n\nExclusion Criteria:\n\n* Presence of acute\u002Fchronic renal impairment (GFR \\<50\u002Fml\u002Fmin\u002F1.73m2).\n* History of cardiovascular disease such as confirmed coronary artery disease, valvular disease, cardiomyopathy, congenital heart disease, and heart failure.\n* Presence of contraindications to CMR.","ALL","18 Years","75 Years",{"count":80,"type":81},300,"ESTIMATED","INTERVENTIONAL",[84],"NA","This study aims to further develop an imaging-guided cohort of rare cardiomyopathies based on the existing database. The investigators will standardize the construction of a cohort that integrates a clinical data repository, serum biobank, myocardial tissue bank, and imaging database. In the current cohort, the investigators will systematically screen for biomarkers indicative of pathological changes in challenging cardiomyopathies. Multidimensional data will be integrated to establish and optimize a heart failure risk assessment model, which will then be validated in a prospective cohort. The effectiveness of the model in assessing different risk groups will be evaluated, with the goal of achieving precise prevention of heart failure from the source.",[87,88,89,90],"Hypertrophic Cardiomyopathy (HCM)","Dilated Cardiomyopathy (DCM)","Metabolic Cardiomyopathy","Restrictive Cardiomyopathy",[92],"rare cardiomyopathy, cardiac multimodal imaging, myocardial impairment","NOT_YET_RECRUITING","2025-01-21",{"date":96,"type":97},"2025-01-27","ACTUAL",{"date":99,"type":81},"2025-02-01",{"date":101,"type":81},"2027-09-30",{"name":5,"class":6},1]